Peptidify
← Back to the journal
REGULATORYAugust 8, 2026 · 5 min read

Melanotan II: banned, unapproved, and still on every feed

The tanning peptide is a case study in regulatory asymmetry — its safer sibling got approved, its aphrodisiac sibling got approved, and MT-II itself got warning letters.

Three siblings, three fates

The melanocortin family tree explains the whole story. Melanotan I — afamelanotide — was cleaned up, dosed properly, and approved (Scenesse in the EU and US) for erythropoietic protoporphyria, a rare light-intolerance disorder. PT-141 — bremelanotide, a metabolite of the melanotan lineage — was approved (Vyleesi) for hypoactive sexual desire disorder. Melanotan II, the full-length parent compound sold in tanning vials: never approved anywhere, repeatedly flagged by the FDA with warning letters about unapproved injectable tanning products.

Why regulators drew the line here

MT-II is a non-selective melanocortin receptor agonist — it hits MC1R (pigmentation) but also MC3R, MC4R and MC5R, which is where the side-effect profile lives: nausea and flushing are common, blood pressure and heart-rate effects are documented, and the MC4R axis is precisely the appetite and sexual-function circuitry its sibling drugs were developed to engage more carefully. Afamelanotide's approval is built on receptor selectivity the tanning compound does not have. The difference is pharmacology, not politics.

The melanoma question

Does artificial melanin induction raise melanoma risk? The honest answer is that long-term data in MT-II users does not exist — which is itself the finding. Accelerated pigmentation of existing nevi is documented in case reports, and activating melanocortin pathways in melanocytic cells is mechanistically uncomfortable enough that regulators treat it as a serious open risk rather than a settled question. A compound whose worst-case scenario is unquantified is a compound without a safety case.

What the codex says

The monograph grades MT-II as research status with limited human evidence and known safety signals — about as far from its sibling drugs as the grading system allows. If someone wants melanocortin pharmacology, the approved versions exist for defined indications with defined monitoring. The tanning vial is the unselected, untested, unmonitored version of a drug class that pharma spent decades trying to make selective.

The takeaway

  • 01Both melanotan siblings made it to approval (afamelanotide, bremelanotide); MT-II itself is unapproved everywhere and under FDA warning letters.
  • 02Non-selective melanocortin activation drives the side-effect profile and the unresolved melanoma-signal question.
  • 03Documented effects include nevus darkening, nausea, flushing and cardiovascular changes.
  • 04Approved melanocortin drugs exist — the gray-market vial is the untested version of that pharmacology.

Verdict — CAUTION

No approval path, no long-term safety data, unresolved melanoma question. The approved siblings tell you what selective melanocortin pharmacology looks like — and MT-II isn't it.

References

  1. FDA. Warning letters on unapproved injectable tanning products containing melanotan II.
  2. EMA/FDA. Scenesse (afamelanotide) and Vyleesi (bremelanotide) prescribing information.
  3. Melanotan I, II and PT-141 monographs — Peptidify codex.